Fyrwald J Erik 4

What Happened
Erik Fyrwald, a director of Eli Lilly & Co. (LLY), received an award/other acquisition of 9.523 shares (stock units) on 2026-01-20. The filing reports a per-share valuation of $1,041.29, for a total value of approximately $9,916. This was an award (A) — not an open-market purchase or sale — reflecting director compensation deferred into stock units.

Key Details

• Transaction date: 2026-01-20 (filed 2026-01-21) — appears to be a timely Form 4 filing.
• Shares/units acquired: 9.523 at $1,041.29 per share; total ≈ $9,916.20.
• Shares owned after transaction: Not specified in the filing.
• Footnote: At Fyrwald’s election, the shares were deferred in lieu of cash under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service.
• Transaction code: A = Award/Grant.

Context
This was a routine director compensation deferral into stock units rather than a market purchase or sale. Deferred director awards are common and don’t necessarily indicate the director’s short-term trading sentiment; they represent compensation that will convert to shares upon separation from service.